UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.

Junyi WuXiangjie XuShasha WuWeiwei ShiGuang ZhangYin CaoZhongxia WangJunhua WuChunping Jiang

Published in: Cancer medicine (2023)

UBE2S enhances malignant properties via the VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and reduces sensitivity to sorafenib in HCC. The findings of this study may open a new approach for HCC diagnosis and provide a potential option for the treatment of HCC.

Keyphrases

signaling pathway
pi k akt
endothelial cells
minimally invasive
epithelial mesenchymal transition
risk assessment
oxidative stress
replacement therapy